Kenvue Inc. (NYSE:KVUE) Stock Position Reduced by River Global Investors LLP

River Global Investors LLP decreased its stake in Kenvue Inc. (NYSE:KVUE) by 5.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,031 shares of the company’s stock after selling 2,813 shares during the quarter. River Global Investors LLP’s holdings in Kenvue were worth $1,111,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock valued at $2,887,773,000 after purchasing an additional 25,238,112 shares in the last quarter. Vanguard Group Inc. increased its holdings in Kenvue by 12.0% in the first quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after buying an additional 17,908,497 shares during the last quarter. Van ECK Associates Corp raised its position in Kenvue by 110.9% during the second quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock valued at $372,880,000 after acquiring an additional 10,783,258 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Kenvue by 16,051.1% in the first quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company’s stock valued at $210,600,000 after acquiring an additional 9,752,836 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Kenvue by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock worth $789,813,000 after acquiring an additional 7,546,362 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on KVUE. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research note on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft increased their price objective on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, UBS Group lifted their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Performance

NYSE KVUE traded up $0.71 during midday trading on Friday, hitting $23.68. The company had a trading volume of 16,635,437 shares, compared to its average volume of 16,248,485. The firm has a fifty day simple moving average of $22.65 and a two-hundred day simple moving average of $20.54. The stock has a market cap of $45.35 billion, a price-to-earnings ratio of 40.83, a P/E/G ratio of 2.94 and a beta of 1.36. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.72.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period in the previous year, the company posted $0.31 earnings per share. The company’s quarterly revenue was down .4% compared to the same quarter last year. Equities analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.46%. Kenvue’s dividend payout ratio (DPR) is currently 141.38%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.